{"analyses":[{"ciLowerLimit":"0.5597","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.8548","groupDescription":"TAS-102+BSC and Placebo+BSC were compared using the stratified log-rank test using the 3 randomization stratification factors (region, ECOG performance status, and prior treatment with ramucirumab). The hazard ratio was estimated using a stratified Cox's proportional hazard (CPH) model and survival was summarized using Kaplan Meier estimates.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.0003","pValueComment":"One-sided P-Value.","paramType":"Hazard Ratio (HR)","paramValue":"0.6917","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.8","upperLimit":"6.2","value":"5.7"},{"groupId":"OG001","lowerLimit":"3.1","upperLimit":"4.1","value":"3.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"170"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death due to any cause. Participants without documented death were censored at last follow-up or cut-off date, whichever comes first. OS was estimated by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 35 mg/m\\^2 of TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.","id":"OG000","title":"TAS-102+BSC"},{"description":"Participants received 35 mg/m\\^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.","id":"OG001","title":"Placebo+BSC"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on the ITT population that included all randomized participants, regardless of whether or not study treatment was administered.","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the data cut-off date (maximum duration: up to approximately 46 months)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}